ML
MLYS.US Mineralys Therapeutics, Inc. Common Stock
- Market cap
- USD 1.29B
- P/E
- -
- P/B
- 2.70x
- ROE
- -89.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MLYS.US undervalued?
Graham numberThe Graham number of Mineralys Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Mineralys Therapeutics, Inc. Common Stock fundamental analysis
No fundamental analysis for Mineralys Therapeutics, Inc. Common Stock yet.
Mineralys Therapeutics, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Mineralys Therapeutics, Inc. Common Stock
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. a…
Full company profileMineralys Therapeutics, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Mineralys Therapeutics, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | - | - | -43.0K | -59.0K | - |
| Operating Income | -2.94M | -18.7M | -31.5M | -84.7M | -192M | -171M | -469M |
| EBITDA | -3.31M | -19.4M | -31.5M | -71.9M | -178M | -155M | -446M |
| Net Income | -3.43M | -19.4M | -29.8M | -71.9M | -178M | -155M | -450M |
| EPS | -0.74 | -3.89 | -5.77 | -1.99 | -3.66 | -2.29 | -5.06 |
| Balance Sheet | |||||||
| Total Assets | 1.49M | 11.1M | 114M | 252M | 206M | 662M | 630M |
| Total Liabilities | 5.08M | 34.1M | 167M | 10.5M | 14.6M | 15.1M | 126M |
| Shareholders' Equity | -3.60M | -22.9M | -52.3M | 241M | 191M | 647M | 504M |
| Cash & Short-term Investments | 1.41M | 10.6M | 110M | 237M | 198M | 657M | 625M |
| Total Debt | 4.50M | - | - | - | - | - | 98.3M |
| Cash Flow | |||||||
| Operating Cash Flow | -2.46M | -14.6M | -29.2M | -81.2M | -166M | -142M | -153M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 96.0K | 15.0K | 0.00 |
| Free Cash Flow | -2.46M | -14.6M | -29.2M | -81.2M | -166M | -142M | -153M |
| Ratios | |||||||
| ROE | - | - | - | -29.8% | -93.0% | -23.9% | -89.4% |
| ROA | -230.6% | -174.5% | -26.0% | -28.6% | -86.4% | -23.4% | -71.5% |
| Debt to Equity | - | - | - | - | - | - | 0.20x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Mineralys Therapeutics, Inc. Common Stock dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 3.83M | 0.83 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Mineralys Therapeutics, Inc. Common Stock
- Insiders 1.11%
- Institutions 98.89%
- Public & others 0.00%
- Shares outstanding 88.6M
- Free float 66.7M
Top funds holding MLYS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| American Funds SMALLCAP World A | 2.50M | 2.83% | +28.72% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.16M | 2.43% | +9.54% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.58M | 1.78% | +2.69% | Oct 2026 |
| iShares Russell 2000 ETF | 1.54M | 1.74% | 0.00% | Oct 2026 |
| Polar Capital Biotech S Inc | 1.35M | 1.52% | 0.00% | Sep 2026 |
| Fidelity Select Health Care | 1.18M | 1.33% | 0.00% | Aug 2026 |
| Worldwide Healthcare Ord | 1.14M | 1.28% | 0.00% | Jul 2026 |
| HBM Healthcare Investments AG Ord | 1.05M | 1.18% | -7.94% | Sep 2026 |
| American Century Small Cap Growth Inv | 963K | 1.09% | +21.53% | Sep 2026 |
| Pictet-Biotech P USD | 943K | 1.07% | +0.38% | Jul 2026 |
| Candriam Eqs L Biotech C USD Cap | 756K | 0.85% | +14.49% | Apr 2026 |
| Franklin Biotechnology Discv A(acc)USD | 731K | 0.83% | -19.42% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 726K | 0.82% | +15.28% | Sep 2026 |
| T. Rowe Price New Horizons | 671K | 0.76% | -11.03% | Sep 2026 |
| Fidelity Small Cap Index | 629K | 0.71% | +0.15% | Aug 2026 |
| Fidelity Advisor Health Care I | 600K | 0.68% | 0.00% | Sep 2026 |
| abrdn Healthcare Investors | 576K | 0.65% | +57.96% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 575K | 0.65% | -0.38% | Oct 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 539K | 0.61% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 473K | 0.53% | -0.19% | Oct 2026 |
Top institutions holding MLYS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Catalys Pacific LLC | 7.80M | 8.81% | -1.32% | Sep 2026 |
| RA Capital Management, LLC | 7.69M | 8.69% | 0.00% | Jun 2026 |
| BlackRock Inc | 5.89M | 6.65% | +31.36% | Jun 2026 |
| Samsara BioCapital, LLC | 5.87M | 6.63% | 0.00% | Jun 2026 |
| FMR Inc | 4.51M | 5.09% | -7.19% | Jun 2026 |
| State Street Corp | 4.14M | 4.68% | +41.07% | Jun 2026 |
| Deerfield Management Co | 3.96M | 4.47% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.76M | 3.11% | +12.32% | Jun 2026 |
| LAURION CAPITAL MANAGEMENT LP | 2.51M | 2.83% | +12.28% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 2.26M | 2.55% | +68.43% | Jun 2026 |
| Orbimed Advisors LLC | 2.11M | 2.38% | +2.80% | Jun 2026 |
| Capital World Investors | 2.00M | 2.26% | +401.69% | Jun 2026 |
| Armistice Capital, LLC | 1.74M | 1.96% | +47.62% | Jun 2026 |
| Nantahala Capital Management, LLC | 1.64M | 1.85% | +83.25% | Jun 2026 |
| Franklin Templeton Inc | 1.64M | 1.85% | -8.36% | Jun 2026 |
| Andera Partners | 1.59M | 1.80% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 1.58M | 1.79% | +21.76% | Jun 2026 |
| SR ONE CAPITAL MANAGEMENT, LP | 1.56M | 1.77% | 0.00% | Jun 2026 |
| Bank of America Corp | 1.51M | 1.70% | +36.82% | Jun 2026 |
| Sphera Funds Management Ltd. | 1.47M | 1.66% | +9.70% | Jun 2026 |
Mineralys Therapeutics, Inc. Common Stock company profile
- Company name
- Mineralys Therapeutics, Inc. Common Stock
- Ticker
- MLYS.US
- Exchange
- USA Stocks
- Listed since
- Feb 10, 2023
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 76
- Fiscal year end
- December
- Address
- 150 N. Radnor Chester Road, Radnor, PA, United States, 19087
- Phone
- 888 378 6240
- Website
- mineralystx.com
About Mineralys Therapeutics, Inc. Common Stock
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Mineralys Therapeutics, Inc. Common Stock management
10- Dr. Jon CongletonPresident, CEO & Director · born 1963
- Dr. Brian Taylor Slingsby M.D., M.P.H., Ph.D.Founder & Executive Director · born 1977
- Mr. Adam Scott LevyCFO & Secretary · born 1978
- Mr. Jeffrey A. Munsie J.D.Chief Legal Officer & Secretary · born 1977
- Dr. Robert McKean Ph.D.Senior Vice President of CMC
- Ms. Danielle MahoneySenior Vice President of Quality Assurance
- Ms. Jessica IbbitsonExecutive Vice President of Operations
- Mr. Eric J. Warren R.Ph.Chief Commercial Officer · born 1972
- Mr. Michael Tortorici Ph.D., Pharm.D.Senior Vice President of Translational Medicine
- Dr. James J. Ferguson III, FACC, M.D.Chief Medical Officer · born 1954